Weigensberg I J
Cancer. 1984 Jan 15;53(2):242-7. doi: 10.1002/1097-0142(19840115)53:2<242::aid-cncr2820530210>3.0.co;2-0.
From 1968 to 1975 105 patients with adenocarcinoma of the endometrium, FIGO clinical Stage I, were randomly allocated to receive, prior to hysterectomy, either a single implant with Heyman capsules and/ or tandem and ovoids, or external megavoltage irradiation. There were no significant differences between the two study arms with respect to distribution of age, uterine size, obesity, frequency of diverticular disease, or histologic grade. Complications were graded rigorously to assure recording all possible treatment related complications and to minimize under-reporting of complications not obviously or directly attributable to the radiation. Fifty-five patients received intracavity irradiation and experienced 5 - and 10-year actuarial disease-free survivals of 80% and 67%, respectively, as compared to 70% and 59% for 50 patients who received external beam. There were only 4 recurrences in the intracavitary group versus 14 in the external beam group. One half of the recurrences in each group were in the pelvis. Major complications occurred with equal frequency in both groups, but minor complications were much more frequent in the external beam group. The differences in survival, recurrences and minor complications were statistically significant, with P values of 0.023, 0.03, and less than 0.02, respectively. With the techniques utilized here, intracavitary radiation is thus seen to be superior to external beam irradiation in terms of higher disease-free survival, lower frequency of recurrence and fewer complications.
1968年至1975年期间,105例国际妇产科联盟(FIGO)临床分期为I期的子宫内膜腺癌患者在子宫切除术前被随机分配,分别接受海曼胶囊单次植入和/或串珠及卵形体植入,或体外兆伏放疗。在年龄分布、子宫大小、肥胖程度、憩室病发生率或组织学分级方面,两个研究组之间没有显著差异。对并发症进行了严格分级,以确保记录所有可能与治疗相关的并发症,并尽量减少对并非明显或直接归因于放疗的并发症的漏报。55例接受腔内放疗的患者5年和10年的精算无病生存率分别为80%和67%,而接受体外照射的50例患者的这一比例分别为70%和59%。腔内放疗组仅有4例复发,而体外照射组有14例复发。每组复发患者中有一半发生在盆腔。两组严重并发症的发生率相同,但体外照射组轻微并发症的发生率要高得多。生存率、复发率和轻微并发症方面的差异具有统计学意义,P值分别为0.023、0.03和小于0.02。因此,就更高的无病生存率、更低的复发率和更少的并发症而言,这里所采用的腔内放疗技术优于体外照射。